Nanoparticles in magnetic resonance imaging: From simple to dual contrast agents

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 1727-1741

  Estelrich, Joan ^a,b   Sánchez Martín, María Jesús ^a   Busquets, Maria Antònia ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CATALAN INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY ICN2   (Spain)

Author keywords

Gadolinium; Iron oxide nanoparticles; Magnetoliposomes; Paramagnetic nanoparticles; Relaxivity; Superparamagnetic nanoparticles

Indexed keywords

CONTRAST MEDIUM; FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IRON OXIDE NANOPARTICLE; LANTHANIDE; LIPOSOME; MACROGOL; MAGNETOLIPOSOME; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PARAMAGNETIC LIPOSOME; PENTETIC ACID; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SUPERPARAMAGNETIC LIPOSOME; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; FERRIC ION; FERRITE; POLYMER;

ARTICLE; COMPLEX FORMATION; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CONTRAST MEDIUM EXTRAVASATION; DISTRIBUTION HALF-LIFE; DOUBLE CONTRAST RADIOGRAPHY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMAGE QUALITY; MAGNETIC FIELD; MAGNETIC RESONANCE ANGIOGRAPHY; MULTIMODAL IMAGING; NANOPHARMACEUTICS; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL DEPTH; OPTICAL RESOLUTION; PARTICLE SIZE; RELAXATION TIME; SIGNAL DETECTION; SIGNAL NOISE RATIO; CHEMISTRY; PROCEDURES; STRUCTURE ACTIVITY RELATION;

CONTRAST MEDIA; FERRIC COMPOUNDS; GADOLINIUM; HUMANS; LANTHANOID SERIES ELEMENTS; LIPOSOMES; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; POLYMERS; SIGNAL-TO-NOISE RATIO; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84928104132     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S76501     Document Type: Article

References (107)

1. Kherlopian AR, Song T, Duan Q, et al. A review of imaging techniques for systems biology. BMC Systems Biol. 2008;2:74.
2. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92:897–965.
3. Huang Y, He S, Cao W, Cai K, Liang XJ. Biomedical nanomaterials for imaging-guided cancer therapy. Nanoscale. 2012;4:6135–6149.
4. Jokerst JV, Gambhir SS. Molecular imaging with theranostic nanoparticles. Acc Chem Res. 2011;44:1050–1060.
5. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545–580.
6. Weissleder R, Ross BD, Rehemtulla A, Gambhir SS. Molecular Imaging: Principles and Practice. Shelton, CT, USA: People’s Medical Publishing House; 2010.
7. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nature Rev. 2003;2:123–131.
8. Cherry SR. Multimodality in vivo imaging systems: twice the power or double the trouble? Annu Rev Biomed Eng. 2006;8:35–62.
9. Weissleder R, Pitter M. Imaging in the era of molecular oncology. Nature. 2008;452:580–589.
10. Lam T, Pouliot P, Avti PK, et al. Superparamagnetic iron oxide based nanoprobes for imaging and theranostics. Adv Colloid Interface Sci. 2013;199–200:95–113.
11. Opina AC, Ghaghada KB, Zhao P, Kiefer G, Annapragada A, Sherry AD. TmDOTA-tetraglycinate encapsulated liposomes as pH-sensitive LipoCEST agents. PLOS One. 2011;6:e27370.
12. Aime S, Castelli DD, Terreno E. Highly sensitive MRI chemical exchange saturation transfer agents using liposomes. Angew Chem Int Ed. 2005;44:5513–5515.
13. Wu Y, Soesbe TC, Kiefer GE, Zhao P, Sherry D. A responsive europium (III) chelate that provides a direct readout of pH by MRI. J Am Chem Soc. 2010;132:14002–14003.
14. Hashim Z, Green M, Chung PH, et al. Gd-containing conjugated polymer nanoparticles: bimodal nanoparticles for fluorescence and MRI imaging. Nanoscale. 2014;6:8376–8386.
15. Stephen ZR, Kievit FM, Zhang, M. Magnetic nanoparticles for medical MR imaging. Mater Today. 2011;14:330–338.
16. Mornet S, Vasseur S, Grasset F, et al. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem. 2004;14:2161–2175.
17. Rümenapp C, Gleich B, Haase A. Magnetic nanoparticles in magnetic resonance imaging and diagnostics. Pharm Res. 2012;29:1165–1179.
18. Laurent S, Vander Elst L, Roch A, et al. Structure, synthesis and characterization of contrast agents for magnetic resonance molecular imaging. In: Carreta P, Lascialfari A, editors. NMR-MRI, SR and Mössbauer Spectroscopies in Molecular Magnets. Milan, Italy: Springer; 2007:71–87.
19. Geraldes CF, Laurent S. Classification and basic properties contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging. 2009;4:1–23.
20. Louie A. Multimodality imaging probes: design and challenges. Chem Rev. 2010;110:3146–3195.
21. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293–2352.
22. Wiegers CB, Welch MJ, Sharp TL, et al. Evaluation of two new gadolinium chelates as contrast agents for MRI. Magn Res Imaging. 1992;10:903–911.
23. Lee GH, Chang Y, Kim TJ. Blood-pool and targeting MRI contrast agents: from Gd-chelates to Gd-nanoparticles. Eur J Inorg Chem. 2012;10:1924–1933.
24. World Health Organization. Pharmaceuticals: Restrictions in Use and Availability. WHO/EMP/QSM/2010.3. Geneva: Switzerland; 2010:14.
25. Winter P, Athey P, Kiefer G, et al. Improved paramagnetic chelate for molecular imaging with MRI. J Magn Magn Mater. 2005;293:540–545.
26. Kobayshi H, Sato N, Kawamoto S, et al. W. 3D MR angiography of mice using macromolecular MR contrast agents with polyamindoamine dendrimer core with reference to their pharmacokinetic properties. Magn Reson Med. 2001;45:454–460.
27. Frías JC, Williams KJ, Fisher EA, et al. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerosis plaques. J Am Chem Soc. 2004;126:16316–16317.
28. Senpan A, Caruthers SD, Rhee I, et al. Conquering the dark side: colloidal iron oxide nanoparticles. ACS Nano. 2009;3:3917–3926.
29. European Medicines Agency. EMA/486286/2012. London, UK: European Medicines Agency; 2012.
30. Pan D, Caruthers SD, Senpan A, et al. Revisiting and old friend: manganese-based MRI contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:162–173.
31. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev. 2006;35:512–523.
32. Park JY, Choi ES, Baek MJ, et al. Water-soluble ultra small paramagnetic or superparamagnetic metal oxide nanoparticles for molecular MR Imaging. Eur J Inorg Chem. 2009;9:2477–2481.
33. Krishnan K. Biomedical nanomagnetics: a spin through possibilities in imaging, diagnostics, and therapy. IEEE Trans Magn. 2010;46:2523–2558.
34. Filippousi M, Angelakeris M, Sikini M, et al. Surfactant effects on the structural and magnetic properties of iron oxide nanoparticles. J Phys Chem C. 2014;118:16209–16217.
35. Shokrollahi H. Structure, synthetic methods, magnetic properties and biomedical applications of ferrofluids. Mater Sci Eng C Mater Biol Appl. 2013;33:2476–2487.
36. Pflipsen C, Forge D, Benali S, et al. Improved stability and relaxivity of a commercial magnetic ferrofluid. J Phys Chem C. 2013;117:20919–20926.
37. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17:484–499.
38. Bulte JW. In vivo MRI cell tracking: clinical studies. Am J Roentgenol. 2009;193:314–325.
39. LaConte LE, Nitin N, Zurkiya O, et al. Coating thickness of magnetic iron oxide nanoparticles affects R2 relaxivity. J Magn Reson Imaging. 2007;26:1634–1641.
40. Hu F, Joshi HM, Dravid VP, et al. High-performance nanostructured MR contrast probes. Nanoscale. 2010;2:1884–1891.
41. Choi HS, Liu W, Misra P, et al. Renal clearance of nanoparticles. Nat Biotechnol. 2007;25:1165–1170.
42. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine. 2008;3:703–717.
43. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284.
44. Hamm B. Iron-oxide-enhanced MR lymphography: just a new toy or a breakthrough? Eur Radiol. 2002;12;957–958.
45. Lind K, Kresse M, Debus NP, Muller RH. A novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing MR lymphography: comparison of physicochemical properties and the in vivo behavior. J Drug Target. 2002;10:221–230.
46. Maes RM, Lewin JS, Duerk JL, et al. A new type of susceptibility-artefact-based magnetic resonance angiography: intra-arterial injection of superparamagnetic iron oxide particles (SPIO) A Resovist in combination with TrueFisp imaging: a feasibility study. Contrast Media Mol Imaging. 2006;1:189–195.
47. Schmitz SA, Albrecht T, Wolf KJ. MR angiography with superparamagnetic iron oxide: feasibility study. Radiology. 1999;213:603–607.
48. Morawski A, Winter P, Crowder K, et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med. 2004;51:480–486.
49. Cai H, An X, Cui J, et al. Facile hydrothermal synthesis and surface functionalization of polyethyleneimine-coated iron oxide nanoparticles for biomedical applications. ACS Appl Mater Interfaces. 2013;5:1722–1731.
50. Li J, He Y, Sun W, et al. Hyaluronic acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging. Biomaterials. 2014;35:3666–3677.
51. Zhang H, Li J, Sun W, et al. Hyaluronic acid-modified magnetic iron oxide nanoparticles for MR imaging of surgically induced endometriosis model in rats. PLOS One. 2014;9:e94718.
52. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995–4021.
53. Xie J, Chen K, Lee HY, et al. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)-beta(3)-rich tumor cells. J Am Chem Soc. 2008;126:11458–11459.
54. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
55. Bin Na H, Chan Song I, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv Mater. 2009;21:2133–2148.
56. Terreno E, Castelli DD, Viale A, et al. Challenges for molecular magnetic resonance imaging. Chem Rev. 2010;110:3019–3042.
57. Yoo D, Lee JH, Shin TH, et al. Theranostic magnetic nanoparticles. Acc Chem Res. 2011;44:863–874.
58. Hadjipanayis CJ, Bonder MJ, Balakrishnan S, et al. Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia. Small. 2008;4:1925–1929.
59. Yang H, Zhang C, Shi X, et al. Water-soluble superparamagnetic manganese ferrite nanoparticles for magnetic resonance imaging. Biomaterials. 2010;31:3667–3673.
60. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res. 2011;44:875–882.
61. Jang JT, Nah H, Lee JH, et al. Critical enhancements of MRI contrast and hyperthermic effects by dopant-controlled magnetic nanoparticles. Angew Chem Int Ed. 2009;48:1234–1238.
62. Das GK, Johnson NJ, Cramen J, et al. NaDyF4 nanoparticles as T2 contrast agents for ultrahigh field magnetic resonance imaging. J Phys Chem Lett. 2012;3:524–529.
63. Bulte JW, Wu C, Brechbiel MW, et al. Dysprosium-DOTA-PANAM dendrimers as macromolecular T2 contrast agents: preparation and relaxometry. Invest Radiol. 1998;33:841–845.
64. Das GK, Zhang Y, Silva LD, et al. Single-phase Dy2O3:Tb3+ nanocrystals as dual-modal contrast agent for field high magnetic resonance and optical imaging. Chem Mater. 2011;23:2439–2446.
65. Gueron M. Nuclear relaxation in macromolecules by paramagnetic ions: a novel mechanism. J Magn Reson. 1975;19:58–66.
66. Taboada E, Rodríguez E, Roig A, et al. Relaxometric and magnetic characterization of ultrasmall iron oxide nanoparticles with high magnetization. Evaluation as potential T1 magnetic resonance imaging contrast agents for molecular imaging. Langmuir. 2007;23:4583–4587.
67. Shubayev VI, Pisanic TR II, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliver Rev. 2009;61:467–477.
68. Cunningham CH, Arai T, Yang PC, et al. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med. 2005;53:999–1005.
69. Huang J, Zhong X, Wang L, et al. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics. 2012;2:86–102.
70. Stuber M, Gilson WD, Schär M, et al. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn Reson Med. 2007;58:1072–1077.
71. McAteer MA, Sibson NR, von zur Muhlen C, et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nature Med. 2007;10:1253–1258.
72. McAteer MA, Schneider JE, Ali ZA, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol. 2008;28:77–83.
73. Vonzur Muhlen, von Elverfeldt D, Moeller JA, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008;118:258–267.
74. Corot C, Robert P, Idèe JM, et al. Recent Advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006;58:1471–1504.
75. Park JY, Daksha P, Lee GH, et al. Highly dispersible PEG surface modified ultra-small superparamagnetic iron oxide nanoparticles useful for target-specific biomedical applications. Nanotechnology. 2008;19:365603.
76. Di Marco M, Sadun C, Port M, et al. Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine. 2007;2:609–622.
77. Gossuin Y, Gillis A, Hocq A, et al. Magnetic resonance relaxation properties of superparamagnetic particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1:299–310.
78. Jun YW, Huh YM, Choi JS, et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc. 2005;127:5732–5733.
79. Choi JS, Lee JH, Shin TH, et al. Self-confirming “AND” logic nanoparticles for fault-free MRI. J Am Chem Soc. 2010;132:11015–11017.
80. Bonmatí MO, Gossuin Y, Morales M, et al. Comparative analysis of the 1H NMR relaxation enhancement produced by iron oxide and core-shell iron–iron oxide nanoparticles. Magn Reson Imaging. 2007;25:1437–1441.
81. Shultz MD, Calvin S, Fatouros PP, et al. Enhanced ferrite nanoparticles as MRI contrast agents. J Magn Magn Mater. 2007;311:464–468.
82. Bae KY, Kim YB, Lee Y, et al. Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T1- and T2-weighted magnetic resonance imaging. Bioconjugate Chem. 2010;21:505–512.
83. Yang H, Zhuang Y, Sun Y, et al. Targeted dual contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles. Biomaterials. 2011;32:4584–4593.
84. Ding D, Kanaly CW, Cummings TJ, et al. Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321. Neurol Res. 2010;32:810–815.
85. Torchilin VP. Liposomes as delivery agents for medical imaging. Mol Med Today. 1996;2:242–249.
86. Kamaly N, Miller AD. Paramagnetic liposome nanoparticles for cellular and tumour imaging. Int J Mol Sci. 2010;11:1759–1776.
87. Strijkers GJ, Mulder WJ, van Heeswijk RB, et al. Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA. 2005;18:186–192.
88. Victor KG, Korb JP, Bryant RG. Translational dynamics of water at the phospholipid interface. J Phys Chem B. 2013;117:12475–12478.
89. Ayyagari LA, Zhang X, Ghaghada KB, Annapragada A, et al. Long-circulating liposomal contrast agents for magnetic resonance imaging. Magn Reson Med. 2006;55:1023–1029.
90. Tilcock C, MacDougall P, Unger E, et al. The effect of lipid composition on the relaxivity of Gd-DTPA entrapped in lipid vesicles of defined size. Biochim Biophys Acta. 1990;1022:181–186.
91. Unger EC, MacDougall P, Cullis P, et al. Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. Magn Reson Imaging. 1989;7:417–423.
92. Van Tilborg GA, Mulder WJ, Deckers N, et al. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjugate Chem. 2006;17:741–749.
93. De Cuyper M, Joniau M. Magnetoliposomes: formation and structural characterization. Eur Biophys J. 1988;15:311–319.
94. Soenen SJ, Hodenius M, De Cuyper M. Magnetoliposomes: versatile innovative nanocolloids for use in biotechnology and biomedicine. Nanomedicine (Lond). 2009;4:177–191.
95. De Cuyper M. The original magnetoliposomes: from the physicochemical basics to theranostic nanomedicine. In: Callejas-Fernández J, Estelrich J, Quesada-Pérez M, Forcada J, editors. Soft Nanoparticles for Biomedical Applications. Cambridge, UK: Royal Society of Chemistry; 2014.
96. Martina MS, Fortin JP, Menager C, et al. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am Chem Soc. 2005;127:10676–10685.
97. Sabaté R, Barnadas-Rodríguez R, Callejas-Fernández J, et al. Preparation and characterization of extruded magnetoliposomes. Int J Pharm. 2008;347:156–162.
98. Chen Y, Bose A, Bothun GD. Controlled release from bilayer-decorated magnetoliposomes via electromagnetic heating. ACS Nano. 2010;4:3215–3221.
99. García-Jimeno S, Escribano E, Queralt J, et al. Magnetoliposomes prepared by reverse-phase followed by sequential extrusion: characterization and possibilities in the treatment of inflammation. Int J Pharm. 2011;405:181–187.
100. Frascione D, Diwoky C, Almer G, et al. Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes. Int J Nanomedicine. 2012;7:2349–2359.
101. Mann S, Hannington JP. Formation of iron oxides in unilamellar vesicles. J Colloid Interface Sci. 1988;122:326–335.
102. Soenen SJ, Himmelreich U, Nuytten N, et al. Intracellular nanoparticle coating stability determines nanoparticle diagnostics efficacy and cell functionality. Small. 2010;6:2136–2145.
103. Fattahi H, Laurent S, Liu F, et al. Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine. 2011;6:529–544.
104. Casals E, Verdaguer A, Tonda R, et al. Atomic force microscopy of liposomes bearing fibrinogen. Bioconjugate Chem. 2003;14:593–600.
105. García-Jimeno S, Escribano E, Queralt J, et al. External magnetic field-induced selective biodistribution of magnetoliposomes in mice. Nanoscale Res Lett. 2012;7:452.
106. De Cuyper M, Soenen SJ, Coenegrachts K, et al. Surface functionalization of magnetoliposomes in view of improving iron oxide-based magnetic resonance imaging contrast agents: anchoring of gadolinium ions to a lipophilic chelate. Anal Biochem. 2007;367:266–273.
107. Soenen SJ, Desender L, De Cuyper M. Complexation of gadolinium (III) ions on top of nanometer-sized magnetoliposomes. Int J Environ Anal Chem. 2007;87:783–796.